What Limits The Size Of A Cell?

Cancer is a typical multicellularproliferative uncontrolled disease. It is generally believed that multicellularlife emerged on Earth 600 million years ago, and the extant sponge-like phylumPorifera was the first multicellular animal to appear. Human diseases are moreor less related to congenital developmental deficiencies, and others arerelated to acquired damage. Have you ever considered what limits the size of acell?

The common ancestor of mouse and humanappeared 100 million years ago.

The genome similarity between humans is at99.99%. Our closest blood relative, the chimpanzee, is 96% genetically similarto us humans. Humans and macaques share 93% of their DNA. Cats share 90% oftheir genes with us humans.

When it comes to protein-coding genes, miceshare 85% similarity with us, but only about 50% similarity when it comes tonon-coding genes. The National Institute of Human Genetics attributed thissimilarity to a common ancestor some 80 million years ago. Scientists explorewhat limits the size of a cell.

Almost all human genes have a clearcounterpart in mice, but protein-coding genes occupy only 1.5% of theirrespective genomes, so the chemosynthetic drugs that can cure mice are usuallyineffective in humans.

Immunotherapy against cancer has a longhistory, starting in 1868 with the work of a man named William Busch. WilhelmBusch, a physician, first reported a significant reduction in tumor size afterintentionally infecting cancer patients with dermatophagoides. Danemia(erysipelas) is an infection involving the superficial lymphatic vessels of thedermis, and the main causative agent is group A beta-hemolytic streptococcus.Predisposing factors are surgical wounds or fissures in the nostrils, externalear canal, below the earlobe, anus, penis, and between the toes. So, whatlimits the size of a cell?

In 1891, William B. Coley, an orthopedicsurgeon at the New York Memorial Hospital in the United States, was diagnosedwith the disease. In 1891, William B. Coley (1862-1936), an orthopedic surgeonat the Memorial Hospital in New York, began treating cancer by injectingbacteria into tumors, creating the "Coley toxin" therapy. This methodwas unstable and could lead to death by infection; the improved mixture ofheated bacterial solution became safe, and a number of people did go intoremission, even long-term remission, from their malignant tumors with notreatment available. As safer and more effective radiation therapy becameavailable in the early 20th century, Colley toxin therapy began to be banned byMSK hospitals until it was later banned by ASCO, although ASCO eventuallyrevoked the ban. Colley's daughter later followed in her father's footsteps,having paid heavily to fund cancer immunotherapy research. What was once aglimpse of the suppressed exploration of early immunotherapy has now beenrecognized by the world and named the highest award in immunology, the WilliamJ. Coley Award, in his honor. Coley Prize.

Based on known immunological principles, itis hypothesized that the mechanism for treating cancer using bacterialinfection is to modulate the body's responsiveness to tumors with bacterialantigens, and that both innate and acquired immunity are activated. Both thebacteria and the self-senescent damaged cells, i.e. the cancerous cells, arecleared by the same immune mechanism, and there is no strict boundary betweenthem, and even a significant part of their functions are in an overlappingstate.

Immunodetection sites are activating andinhibiting receptor regulatory switches located on effector T-cells, and theuse of activating antibodies can initiate functions downstream of the receptor(activation or inhibition), making the T-cells aggressive and inhibiting themquiet. With 100 trillion different types of eukaryotic cells in the body, theprecise regulation of the immune attack performance of T cells is a processregulated by multiple mechanisms, of which the immune detection site is one. Someexperimental data verifies what limits the size of a cell.

The first immune detection site to be usedin medical practice was CTLA-4, which was discovered by James Allison and tookabout 10 years to confirm its function. The second molecule of this class wasPD1/PD-L1, which was first discovered by the Japanese scholar, BenjaminHenshaw, who confirmed its utility, and PD-L1, which was discovered by theChinese-American scholar, Chen-Shen-Ping, who also confirmed its utility.

The current major ICIs are designed basedon these targets. Immunodetection sites consist of many, other molecules alsohave potential development value, and related drugs are under development.